Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants. \>/= 18 years of age~* Histologically confirmed metastatic or unresectable papillary thyroid cancer for which standard curative or palliative measures do not exist or are no longer effective; participants whose tumors exhibit areas of other histology may be enrolled, provided the tumor histology remains predominantly papillary~* Positive for BRAF V600 mutation (Roche Cobas 4800 BRAF V600 Mutation Test)~* Radioactive Iodine resistant disease~* Prior therapy excluding (Cohort 1, TKI Naive) or including (Cohort 2, TKI Experienced) TKI~* Clinically relevant disease progression according to RECIST criteria within the prior 14 months~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Adequate hematological, renal and liver function~Exclusion Criteria:~* Histological diagnosis other than papillary PTC, including squamous cell variants of PTC or PTC with areas of squamous metaplasia~* Active or untreated central nervous system metastases~* History of or known carcinomatous meningitis~* Anticipated or ongoing administration of any anti-cancer therapies other than those administered in the study~* Active squamous cell skin cancer that has not been excised or adequately healed post excision~* Previous treatment with any agent that specifically and selectively targets the MEK or BRAF pathway~* Prior radiotherapy to the only measurable lesion~* Clinically relevant cardio-vascular disease or event within the prior 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tyrosine Kinase Inhibitor (TKI) Naive (Type: EXPERIMENTAL): Vemurafenib in participants naive to any prior systemic TKI therapy.
- TKI Experienced (Type: EXPERIMENTAL): Vemurafenib in participants previously treated with TKI therapy active against vascular endothelial growth factor receptor 2 (VEGFR).

Based on this trial design, predict the completion outcome and termination type (if applicable).